MindImmune Therapeutics

Targeting immune drivers of Alzheimer's disease

Kingston, United States · Founded 2016 · $12.4M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$12.4M
Last Round
$12.4M Series AJun 2022
Rounds
1

About

MindImmune Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel immunotherapies for neurodegenerative diseases, with a primary focus on Alzheimer's Disease. Founded on the discovery that peripheral immune cells drive neurodegeneration, the company's lead program MITI-101 is a first-in-class monoclonal antibody that prevents neuroinflammation, neurite damage, and vascular pathology by blocking harmful immune cells from infiltrating the brain. Backed by investors including Dolby Family Ventures, Pfizer Ventures, and the Alzheimer's Drug Discovery Foundation, MindImmune completed a $30M Series A round in December 2025 to advance MITI-101 toward its first-in-human clinical trial in 2027.

Summary

MindImmune Therapeutics is a Biotech company based in Kingston, United States, founded in 2016. It has raised $12.4M in total across 1 round, most recently a $12.4M Series A round in Jun 2022.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJun 2022
$12.4M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MindImmune Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/mindimmune-therapeutics"><img src="https://indexed.vc/api/badge/company/mindimmune-therapeutics" alt="MindImmune Therapeutics on Indexed.vc" width="260" height="76" /></a>